1/The exponential growth in both the number and size of M&A deals in the BioTech and Pharma ecosystem is just staggering! This excellent article - by FT's Oliver Barnes and Aanu Adeoye, describes the problematic situation that big Pharma companies - $PFE $LLY $NVO $JNJ $NVS $BMY $AZN $ABBV $MRK $SNY and others, are now in. The “patent cliff” or IP Lost of Exclusivity (LOE) scenario is predicted to cause more than $330B (!) in combined revenue loss, thus creating an immense pressure on both the clinical pipeline of Pharma companies as well as on their future revenue streams. This is probably the most significant catalyst behind the vast scale of M&A deals in the BioTech and Pharma ecosystem as big Pharma are trying to aggressively replenish their pipelines - mostly via M&A deals with smaller BioTech companies, in order to compensate for their potential losses. This frenzy can be seen in the sheer number of deals in which BioTech companies have been acquired for at least $1B in 2026 (37) - a number which is already much higher than the previous annual record of 35 companies set only last year, with 4 months still remaining for more possible M&A deals in the sector. Another important indicator of this positive stance in the BioTech and Pharma ecosystem could be seen in the new five-year high that the $XBI biotech index has set this month. 🧵👇
$GLW Q2 EARNINGS
• Revenue $4.74B vs Est. $4.61B
• EPS $0.78 vs Est. $0.76
• Optical Communications: $2.07B (+32% YoY)
• Gross Margin 40% vs Est. 38%
Q3 Guidance
• Revenue $4.95B vs Est. $4.99B
• EPS $0.87 vs Est. $0.85
Corning says it’s entering a new phase of accelerating growth and expects a 19% sales CAGR through 2030.
Fubon- "the production push out in Rubin will bring some negative impact to the supply chain as Rubin has higher dollar content compared to Blackwell"
$MU: "recent checks suggest that $NVDA HBM4 cost will increase to US$31-32 per GB from US$17-18 per GB (HBM 3e) in 2026."
"We estimate nVidia’s Rubin GPU price will skyrocket to US$78-80K assuming nVidia is still able to maintain its GM at 75-80% in chips."
"For other GPU and custom-ASIC projects, we believe their HBM cost will be higher than nVidia’s and may reach US$35-36 per GB, meaning the HBM cost will double in 2027."
"Despite the market’s AI inflation concern recently, in our view, the token cost is still a more important factor in driving CSP’s capex, and we remain positive about AI market demand."
"Our checks suggest nVidia still plans to put the same amount of compute dies in its new rack architecture or system"
"Between the two racks, nVidia plans to use NPO/CPO for scale out connection while inside the rack, cable connection is still used for scale up connection"
"Based on our checks, Google plans to have 12-15mn TPUs in 2028. Entering 2028, Google’s TPUs will enter the V9 generation with four compute dies, suggesting that their capacity consumption will more than double in 2028 vs. 2027."
"Based on our checks, $INTC EMIB capacity will reach 10-12k by the end of 2026, and the plan is to double its capacity to 24-25k per month by the end of 2027."
"we see $TSM slowing down its SoIC expansion to prioritize the CoWoS expansion"
$AVGO: "we think it is possible that MediaTek could further raise its custom-ASIC market share in 2027."
Kospi韩国股市目前下跌9%
KOSPI目前已经进入一个比较清晰的下降通道,短期趋势依然偏弱,但这种通道最终都会迎来突破。从技术面来看,下方重要支撑正在逐渐汇聚:EMA 200约在6000,Weekly EMA 50约在5700,SMA 200也在5700附近,而5500还有前期缺口等待回补。这几个关键支撑区域重叠,5700-6000成为本轮调整最值得关注的区域。
另外,KOSPI已经连续下跌接近六周,技术指标也逐步进入超卖区,短线进一步杀跌的空间正在缩小。如果指数回踩EMA 200甚至Weekly EMA 50附近,我认为出现一轮像样的技术性反弹,甚至中期趋势反转的概率都会明显提高。从时间窗口来看,本周或下周很有可能形成阶段性低点。